Moneyta · stock research · no sign-up needed
AVTX
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue
-
Net income
-
as filed with the SEC
Institutions holding
127
+26 last quarter
Overview · Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute res…
Management team
- Dr. Dino C. Miano Ph.D. · Senior Vice President of CMC & Technical OperationsFind on LinkedIn
- Ms. Colleen Matkowski · Senior Vice President of Global Regulatory Affairs & Quality AssuranceFind on LinkedIn
- Dr. Lisa Hegg Ph.D. · Senior Vice President of Program Management, Corporate Infrastructure & Clinical OperationsFind on LinkedIn
- Dr. Garry A. Neil M.D. · Chairman of the Board, President & CEOFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
members see every cardRead the full desk report on AVTX
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.